Potentiation of the in vitro activity of the multi-targeted antifolate MTA (LY231514) by dipyridamole

被引：0
|
作者：
Smith, PG [1 ]
Newell, DR [1 ]
Barnes, MJ [1 ]
Calvert, AH [1 ]
Curtin, NJ [1 ]
机构：
[1] Univ Newcastle Upon Tyne, Canc Res Unit, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England
来源：
ANNALS OF ONCOLOGY | 1998年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
588
引用
收藏
页码：154 / 154
页数：1
相关论文
共 50 条
  • [31] Biochemical pharmacology studies of a multitargeted antifolate: LY231514
    Shih, C
    Beardsley, GP
    Chen, VJ
    Ehlhardt, WJ
    MacKellar, WC
    Mendelsohn, LG
    Ratnam, M
    Schultz, RM
    Taylor, EC
    Worzalla, JF
    CHEMISTRY AND BIOLOGY OF PTERIDINES AND FOLATES 1997, 1997, : 181 - 187
  • [32] Resistance to the multitargeted antifolate (MTA, LY231514): Multifactorial in human leukemia, breast, and colon carcinoma cells
    Schultz, RM
    Chen, VJ
    Bewley, JR
    Roberts, EF
    Shih, C
    Dempsey, JA
    ANNALS OF ONCOLOGY, 1998, 9 : 135 - 135
  • [33] Multiple folate enzyme inhibition: Mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA)
    Shih, C
    Habeck, LL
    Mendelsohn, LG
    Chen, VJ
    Schulz, RM
    ADVANCES IN ENZYME REGULATION, VOL 38, 1998, 38 : 135 - 152
  • [34] A phase I and pharmacokinetic (PK) study of the multitargeted antifolate (MTA, LY231514) with folic acid (FA)
    Hammond, L
    Villalona-Calero, M
    Eckhardt, SG
    Siu, L
    Hidalgo, M
    Thornton, D
    Walling, J
    Baker, S
    Coltman, C
    Von Hoff, D
    Rowinsky, E
    ANNALS OF ONCOLOGY, 1998, 9 : 129 - 129
  • [35] A Phase I and pharmacokinetic study of LY231514, the multitargeted antifolate
    McDonald, AC
    Vasey, PA
    Adams, L
    Walling, J
    Woodworth, JR
    Abrahams, T
    McCarthy, S
    Bailey, NP
    Siddiqui, N
    Lind, MJ
    Calvert, AH
    Twelves, CJ
    Cassidy, J
    Kaye, SB
    CLINICAL CANCER RESEARCH, 1998, 4 (03) : 605 - 610
  • [36] Phase II trial of the multi-targeted antifolate MTA (LY231514) in patients with non-small cell lung cancer (NSCLC) who have failed previous platinum or non-platinum chemotherapy
    Mattson, K
    Manegold, C
    Postmus, P
    Smit, E
    Millward, M
    Saarinen, A
    ANNALS OF ONCOLOGY, 1998, 9 : 98 - 98
  • [37] Phase II study of the multitargeted antifolate LY231514 (ALIMTA™, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer
    Miller, KD
    Picus, J
    Blanke, C
    John, W
    Clark, J
    Shulman, LN
    Thornton, D
    Rowinsky, E
    Loehrer, PJ
    ANNALS OF ONCOLOGY, 2000, 11 (01) : 101 - 103
  • [38] Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis
    Mendelsohn, LG
    Shih, C
    Chen, VJ
    Habeck, LL
    Gates, SB
    Shackelford, KA
    SEMINARS IN ONCOLOGY, 1999, 26 (02) : 42 - 47
  • [39] Role of folic acid in modulating the toxicity and efficacy of the multitargeted antifolate, LY231514
    Worzalla, JF
    Shih, C
    Schultz, RM
    ANTICANCER RESEARCH, 1998, 18 (5A) : 3235 - 3239
  • [40] Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: An NCIC Clinical Trials Group study
    Cripps, C
    Burnell, M
    Jolivet, J
    Batist, G
    Lofters, W
    Dancey, J
    Iglesias, J
    Fisher, B
    Eisenhauer, EA
    ANNALS OF ONCOLOGY, 1999, 10 (10) : 1175 - 1179
12345